Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has proved helpful hard but unsuccessfully to produce an one off therapy, variously called Pro 140, leronlimab, and Vyrologix.

In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in terminology of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be being used is an open question.

While CYDY  happens to be dawdling, market opportunities for leronlimab as a combination treatment in the healing of multi-drug-resistant HIV happen to be closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of the past several shares of mine. The first CytoDyn post of mine, “CytoDyn: What In order to Do When It’s Too Good to be able to Be True?”, set away what follows prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan offered such a highly promotional picture in the Uptick Newswire job interview which I came away with an inadequate impression of the company.

Irony of irony, the poor impression of mine of the business enterprise has grown steadily, yet the disappointment has not been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > 6 bagger yet still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much storied treatment (which I shall refer to as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for the therapy and avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV- infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of this know-how as well as connected intellectual property from Progenics to CytoDyn, and roughly twenty five million mg of majority drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 zillion) plus the very first new drug program approval ($5 million), and even royalty payments of 5 % of net sales upon commercialization.

Since that moment, CytoDyn’s guiding nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to acquire a market place cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous therapies and multiple indications, it has this individual treatments and a “broad pipeline of indications” as it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a potentially beneficial therapy in dozens of indications.

Its opening banner on its website (below) shows an energetic business with diverse interests albeit focused on leronlimab, multiple disease types, multiple delivering presentations and multiple publications.

Might all this be smoke and mirrors? That’s a question I have been asking myself from the really beginning of the interest of mine in this particular company. Judging by the multiples of thousands of several commentary on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I am a lot from alone in this question.

CytoDyn is a traditional battleground, or perhaps some might say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label some negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *